ro for glp-1 launches the Supply Tracker Ro Online GLP-1 Clinic Review
Description
CSE, Chinese Society of Endocrinology
V.MartinA
New GLP1-based multi-agonist therapies seem to be substantially more effective than older GLP1R agonists in reducing body weight but their safety requires ongoing scrutiny in trials assessing outcomes in individuals with obesity
The typical reduction in A1c with metformin therapy is in the range of 1 to 2.0% (22,53)
And, it may expand access as early as January 2026
The roughly $7B Metsera deal brings ultra-long-acting obesity assets into a 2026 pipeline featuring around 20 pivotal study starts
